Suven Pharmaceuticals Ltd

Cohance Lifesciences Ltd has announced the completion of an inspection by the United States Food and Drug Administration (USFDA) at its formulation (FDF) plant in Shamshabad, Telangana. The inspection, which took place from August 27 to September 4, 2026, concluded with the issuance of a Form FDA 483, detailing four observations. The company has confirmed that it has initiated corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline. Cohance Lifesciences reiterated its commitment to quality and regulatory compliance.

Cohance Lifesciences Limited announced two strategic transactions to bolster its Antibody-drug Conjugate (ADC) strategy, involving a USD 13 million investment in NJ Bio and a USD 5 million controlling investment in Aruka Bio. These investments, funded by internal accruals, aim to deepen NJ Bio's integration with Cohance for customer-facing services and focus Aruka's proprietary pipeline development through partnerships. Cohance will increase its ownership in NJ Bio to 67.3% and gain a 65% direct ownership in Aruka Bio, which will become a direct subsidiary. These moves are expected to strengthen business performance and position Aruka's platform for future collaborations. Completion is anticipated by the end of September 2026.

Cohance Lifesciences Limited announced two strategic transactions to bolster its Antibody-drug Conjugate (ADC) strategy. The company will invest an additional USD 13 million in its subsidiary NJ Bio, increasing its stake from 56% to 67.3%. Concurrently, Cohance will invest USD 5 million in Aruka Bio, Inc., a step-down associate, acquiring approximately 65% ownership. These investments, funded by internal accruals, aim to integrate NJ Bio's customer-facing capabilities with Cohance's manufacturing platform and advance Aruka Bio's proprietary pipeline. Dr. Naresh Jain will continue as CEO of NJ Bio and also assume the CEO role at Aruka Bio. Both transactions are subject to regulatory approvals and definitive agreements.

Cohance Lifesciences Ltd has filed its Integrated Annual Report and Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report, compliant with the Companies Act, 2013 and SEBI Listing Regulations, is being disseminated electronically to members. The company highlights FY26 as a year of transition, marked by investments in future capabilities, integration of scientific legacies, new therapeutic platforms, and a strengthened leadership structure. Challenges faced included customer-led inventory normalization, commercial-order phasing, and regulatory/operational hurdles. The report emphasizes Cohance's role at the intersection of pharmaceutical innovation and global healthcare delivery, focusing on advancing the science of progress through chemistry and molecular complexity.

Cohance Lifesciences Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as required by SEBI regulations. The report details the company's performance across environmental, social, and governance (ESG) parameters. Key disclosures include its business activities, market reach, employee details, and operational locations. The company operates primarily in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products, with a significant portion of its turnover derived from exports. The BRSR report has undergone reasonable assurance assessment by Sustainability Actions Private Limited.

Cohance Lifesciences Ltd. has issued a notice for its 8th Annual General Meeting (AGM) scheduled for Thursday, September 17, 2026, at 4:00 PM IST. The meeting will be conducted via Video Conference (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the financial year 2025-26, and the re-appointment of Ms. Shweta Jalan as a Director. The integrated annual report for FY2025-26 is available on the company's website. E-voting will be open from September 14 to September 16, 2026, with a cut-off date of September 10, 2026.

DSP Trustee Private Limited, on behalf of various DSP Mutual Fund schemes and DSP Alternative Investment Fund, has disclosed the sale of 28,99,996 shares, representing 0.76% of the total paid-up capital, in Cohance Lifesciences Limited. This transaction resulted in a decrease of their shareholding from approximately 4.29% to 3.53%. The sale occurred on August 7, 2026, and the disclosure is made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as the change exceeded the 2% threshold. DSP Asset Managers Private Limited acts as the investment manager for these funds.

Cohance Lifesciences Ltd announced that its Board of Directors, in a meeting held on August 5, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved the reorganization at Sapala Organics Private Limited, a subsidiary, and the convening of the 8th Annual General Meeting on September 17, 2026. The meeting commenced at 3:30 pm IST and concluded at 5:25 pm IST.

Cohance Lifesciences Ltd announced that its Board of Directors, in a meeting held on August 5, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved reorganization at its subsidiary, Sapala Organics Private Limited, and decided to convene the 8th Annual General Meeting on September 17, 2026. The financial results, limited review reports, press release, and investor presentation were enclosed with the filing. The meeting commenced at 3:30 pm IST and concluded at 5:25 pm IST.

Cohance Lifesciences Ltd announced the completion of a USFDA inspection at its Pashamylaram, Hyderabad manufacturing facility. The inspection, conducted from July 27 to August 5, 2026, resulted in a Form FDA 483 with five observations. Importantly, none of these observations pertain to data integrity issues. The company is currently assessing the observations and preparing a comprehensive response with corrective and preventive actions (CAPAs) for submission within the stipulated timeline. Cohance Lifesciences expressed confidence in the addressability of the observations and its commitment to working constructively with the USFDA for timely resolution, emphasizing its dedication to quality, regulatory compliance, and patient safety.